Philogen S.p.A.

Equities

PHIL

IT0005373789

Biotechnology & Medical Research

Real-time Borsa Italiana Other stock markets 06:55:35 2024-05-29 am EDT			5-day change	1st Jan Change
20.8 ^EUR	+1.46%		+12.74%	+12.43%

12:07pm	Sales in Milan; but Philogen is at annual peak	AN
08:34am	Futures down; Brent advances to USD84 area	AN

Philogen S p A : to present at the CEO Roundtable Zoom Session organised by Goldman Sachs in June, 2021

June 08, 2021 at 05:49 am EDT

2021, Events

Philogen announces its participation at the CEO Roundtable Zoom Session organised by Goldman Sachs from June 8 to 29, 2021.
Co-founder, CEO and CSO, Prof. Dario Neri has been invited to share and discuss all the dimensions of the unprecedented current market environment, compare notes on the ongoing global situation and key focuses for 2021 and beyond. Dario Neri to attend three roundtables on June 8, 17 and 29, 2021.

Attachments

Original document
Permalink

Disclaimer

Philogen S.p.A. published this content on 08 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 June 2021 09:48:07 UTC.

Latest news about Philogen S.p.A.

Sales in Milan; but Philogen is at annual peak	06:07am	AN
Futures down; Brent advances to USD84 area	02:34am	AN
Mib in the red; BPER and Intesa resist declines	May. 28	AN
Mib down but Iveco and Pirelli soar	May. 24	AN
Philogen, NFP and liquidity drop in first quarter	May. 07	AN
Indices up; Italy, industrial sales down	Apr. 12	AN
Transcript : Philogen S.p.A., 2023 Earnings Call, Apr 03, 2024	Apr. 03
Philogen reduces loss in 2023; NFP remains positive	Mar. 27	AN
Philogen S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Mib re-emerges in green; Saipem resumes rally	Mar. 07	AN
Futures await lists in red	Feb. 27	AN
Europeans down; Sogefi flies in Piazza Affari.	Feb. 26	AN
Philogen S.p.A. Provides Update on Pre-Planned Interim Analysis of the Phase III FIBROSARC Trial Investigating Onfekafusp Alfa in Patients with First-Line Advanced or Metastatic Soft Tissue Sarcoma	Feb. 20	CI
Mib in the red at 31,600; TIM still on top	Feb. 19	AN
European indexes down; TIM tops Mib	Feb. 19	AN
Futures bullish; PMI data coming in.	Jan. 24	AN
Mib gives ground; Saipem resists declines	Jan. 23	AN
Mib loses 30,000 points; MPS shines	Jan. 17	AN
Mib falls below 30,400; Amplifon tops	Jan. 08	AN
Piazza Affari down slightly; banks on the Mib do well	Jan. 08	AN
Philogen S.P.A. Announces Receipt of the Good Manufacturing Practice Certificate for Its New Production Facility in Rosia (Siena, Italy) by Competent Authorities	Dec. 05	CI
Cucinelli on Mib in December; Philogen, d'Amico and SAES on Mid	Nov. 23	AN
Philogen, net financial position falls in third quarter	Nov. 08	AN
Philogen has purchased 3,300 shares of its own common stock	23-10-23	AN
Transcript : Philogen S.p.A. - Special Call	23-10-18

Chart Philogen S.p.A.

Duration

Period

More charts

Company Profile

Philogen SpA is an Italy-based company, operating in the biotechnology sector. The Company develops products and technologies for the diagnosis and therapy of serious human diseases. It has three anti-cancer antibody derivatives, produced with an in-house industrial process, into Phase I/II clinical studies. The majority of its technologies and products are based on high-affinity human monoclonal antibody fragments. Philogen SpA developed a patented technology, Iterative Colony Filter Screening, for the isolation of monoclonal antibodies, which requires neither immunization nor phage display. The Company's subsidiaries are Philotec, Philomed and Philochem. Philogen SpA is headquartered in Siena, Italy.

Sector

Biotechnology & Medical Research

Calendar

2024-06-07 - Chemical Biology Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Philogen S.p.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

20.5 EUR

Average target price

23.5 EUR

Spread / Average Target

+14.63%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PHILOGEN S.P.A.	+12.43%	898M
VERTEX PHARMACEUTICALS INCORPORATED	+9.83%	115B
REGENERON PHARMACEUTICALS, INC.	+10.80%	105B
BIONTECH SE	-10.84%	22.71B
ARGENX SE	-1.31%	21.83B
GENMAB A/S	-10.51%	18.18B
WUXI APPTEC CO., LTD.	-41.92%	16.52B
BEIGENE, LTD.	-15.11%	16.01B
NEUROCRINE BIOSCIENCES, INC.	+6.62%	14.14B
SAREPTA THERAPEUTICS, INC.	+17.53%	10.71B

Bio Therapeutic Drugs